GALT Stock Forecast: Galectin Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.69
−4.27% on the day

The median 12-month analyst price target for Galectin Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 82 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$271.4M
Ticker Nerd rank
82/ 100
Median analyst target
$11
Analysts covering
1
Revenue$0.0
Operating income−$4.0M
Net income−$9.1M
Free cash flow−$2.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.8%
1M
−21.6%
YTD
−35.3%
1Y
−53.1%
From 52W high
−58.7%
From 52W low
+29.3%
$2.08
$6.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Galectin Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
82/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
81
Revisions
77
Volatility
76
Accruals
75
Growth
71
Issuance
68
Momentum
49
Quality
19

Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GALT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GALT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26GALTHigh $11Median $11Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$11
Low
$11
Median
$11
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026HC Wainwright & Co.ReiteratesBuy$11
17 Dec 2025HC Wainwright & Co.MaintainsBuy—
14 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.AssumesBuy$6.00
2 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.DowngradeNeutral—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.ReiteratesBuy—
9 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
17 May 2023HC Wainwright & Co.ReiteratesBuy—
3 Mar 2023HC Wainwright & Co.ReiteratesBuy—
17 May 2022HC Wainwright & Co.MaintainsBuy—
16 Apr 2021HC Wainwright & Co.MaintainsBuy—
13 Aug 2020HC Wainwright & Co.MaintainsBuy—
3 Apr 2020B. Riley FBRMaintainsBuy—
3 Apr 2020B. Riley SecuritiesMaintainsBuy—
17 Mar 2020HC Wainwright & Co.MaintainsBuy—
13 Feb 2019B. Riley FBRInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GALT.

Market Radar

This page is one stock. Monday covers all of them.

GALT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GALT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Galectin Therapeutics, Inc. returned −53.1% against +6.9% for the S&P 500, dividends included.

GALT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26GALTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GALT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−71.5%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Galectin Therapeutics, Inc. has a market value of $271.4M and an enterprise value of $300.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$27.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.9M.

  • Shares outstanding: 66.3M.

  • Galectin Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

GALT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GALTGalectin Therapeutics, Inc.$271.4M82
NAUTNautilus Biotechnology, Inc.$269.4M70
RLMDRelmada Therapeutics, Inc.$274.8M55
AGENAgenus, Inc.$267.2M82
PEPGPepGen Inc.$261.8M53
FULCFulcrum Therapeutics, Inc.$281.5M35
GLSIGreenwich LifeSciences, Inc.$282.6M53

Take a look at GALT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Galectin Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GALT

What is the GALT stock price forecast for 2026-2027?

The median 12-month analyst price target for Galectin Therapeutics, Inc. is $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GALT stock a buy right now?

Of the 1 analyst covering Galectin Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galectin Therapeutics, Inc. 82 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GALT?

As at 21 Nov 2026, Galectin Therapeutics, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).

Will GALT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $11, and Ticker Nerd's factor model ranks Galectin Therapeutics, Inc. 82 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GALT stock forecast for 2030?

No analyst covering Galectin Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.

How has GALT stock performed over the past year?

Galectin Therapeutics, Inc. returned -53.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Galectin Therapeutics, Inc. do?

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy.

Company

About Galectin Therapeutics, Inc.

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy. Its lead product candidate, belapectin, is a galectin-3 inhibitor being studied in programs related to metabolic dysfunction-associated steatohepatitis, liver fibrosis, cirrhosis, and portal hypertension. The company also supports research into additional galectin-related treatments, including oral small-molecule inhibitors through collaborative efforts. Galectin Therapeutics is based in Norcross, Georgia, and operates within the biotechnology sector, where it focuses on discovery and development rather than commercial-scale product sales.

CEO Mr. Joel Lewis CPA · 9 employees · United States · https://galectintherapeutics.com